Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HolleyPharm To Inject RMB 50 Million Into Holley-Cotec

This article was originally published in PharmAsia News

Executive Summary

To further consolidate its artemisinin-related business, HolleyPharm will pump in RMB 50 million into its Beijing subsidiary Beijing Holley-Cotec Pharmaceuticals. With the capital injection, the latter's registered capital will be increased from the current RMB 5 million to RMB 50 million in the initial stage, and eventually to RMB 100 million. In addition, HolleyPharm will gradually transfer its stakes in artemisinin-related firms including Holley Wuling Mountain, Holley (Jishou), Holley Nanhu and Beibei pharmaceutical base to Holly-Cotec. The reorganization aims to establish an artemisinin-centered business platform with higher efficiency, better economic performance and greater competitiveness. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts